
Cyril Pottier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3856025/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without <i>GRN</i> mutations. Brain, 2022, 145, 2472-2485.	7.6	6
2	Underlying genetic variation in familial frontotemporal dementia: sequencing of 198 patients. Neurobiology of Aging, 2021, 97, 148.e9-148.e16.	3.1	17
3	Impact of variant-level batch effects on identification of genetic risk factors in large sequencing studies. PLoS ONE, 2021, 16, e0249305.	2.5	5
4	Clinicopathologic correlations in a family with a <i>TBK1</i> mutation presenting as primary progressive aphasia and primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 568-575.	1.7	24
5	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	5.2	40
6	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
7	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
8	ldentification of compound heterozygous variants in <i>OPTN</i> in an ALS-FTD patient from the CReATe consortium: a case report. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 469-471.	1.7	15
9	Identification of missing variants by combining multiple analytic pipelines. BMC Bioinformatics, 2018, 19, 139.	2.6	10
10	Three VCP Mutations in Patients with Frontotemporal Dementia. Journal of Alzheimer's Disease, 2018, 65, 1139-1146.	2.6	19
11	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	8.1	493
12	Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Acta Neuropathologica Communications, 2017, 5, 96.	5.2	38
13	Alzheimer disease: modeling an AÎ ² -centered biological network. Molecular Psychiatry, 2016, 21, 861-871.	7.9	47
14	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	3.1	69
15	Genetics of <scp>FTLD</scp> : overview and what else we can expect from genetic studies. Journal of Neurochemistry, 2016, 138, 32-53.	3.9	118
16	Prosaposin is a regulator of progranulin levels and oligomerization. Nature Communications, 2016, 7, 11992.	12.8	68
17	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	12.8	174
18	Mutation in the 3'untranslated region of APP as a genetic determinant of cerebral amyloid angiopathy. European Journal of Human Genetics, 2016, 24, 92-98.	2.8	26

CYRIL POTTIER

#	Article	IF	CITATIONS
19	The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. American Journal of Neurodegenerative Disease, 2016, 5, 94-101.	0.1	4
20	De novo deleterious genetic variations target a biological network centered on Aβ peptide in early-onset Alzheimer disease. Molecular Psychiatry, 2015, 20, 1046-1056.	7.9	89
21	PRKAR1B mutations are a rare cause of FUS negative neuronal intermediate filament inclusion disease. Brain, 2015, 138, e357-e357.	7.6	9
22	Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathologica, 2015, 130, 77-92.	7.7	267
23	A de novo nonsense PDGFB mutation causing idiopathic basal ganglia calcification with laryngeal dystonia. European Journal of Human Genetics, 2014, 22, 1236-1238.	2.8	46
24	PDGFB Partial Deletion: a New, Rare Mechanism Causing Brain Calcification with Leukoencephalopathy. Journal of Molecular Neuroscience, 2014, 53, 171-175.	2.3	50
25	Overall mutational spectrum of SLC20A2, PDGFB and PDGFRB in idiopathic basal ganglia calcification. Neurogenetics, 2014, 15, 215-216.	1.4	22
26	TREM2 R47H Variant as a Risk Factor for Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 45-49.	2.6	136
27	Mutation of the <i>PDGFRB</i> gene as a cause of idiopathic basal ganglia calcification. Neurology, 2013, 80, 181-187.	1.1	239
28	Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain, 2013, 136, 3395-3407.	7.6	183
29	Amyloid-β Protein Precursor Gene Expression in Alzheimer's Disease and Other Conditions. Journal of Alzheimer's Disease, 2012, 28, 561-566.	2.6	22
30	High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Molecular Psychiatry, 2012, 17, 875-879.	7.9	253